Table 1 Characteristics of the study population
|  | Training phase (n = 56) |  | Validation phase (n = 168) |  | ||
|---|---|---|---|---|---|---|
KIRC | NC | Â | KIRC | NC | ||
Total number | 28 | 28 | Â | 84 | 84 | Â |
Age at diagnosis |  |  | p = 0.68 |  |  | p = 0.38 |
|  | 58.93 ± 14.0 | 60.4 ± 13.0 |  | 62.19 ± 12.7 | 60.4 ± 13.5 |  |
Gender |  |  | p = 0.79 |  |  | p = 0.21 |
 Male | 13 (46.4%) | 12(42.9%) |  | 48 (57.1%) | 41 (48.9%) |  |
 Female | 15 (53.6%) | 16(57.1%) |  | 36 (42.9%) | 43 (51.1%) |  |
Location | Â | Â | Â | Â | Â | Â |
 Left | 16 (57.1%) |  |  | 43 (51.1%) |  |  |
 Right | 12 (42.9%) |  |  | 41 (48.9%) |  |  |
Fuhrman grade | Â | Â | Â | Â | Â | Â |
 Grade I | 4 (14.3%) |  |  | 10 (11.9%) |  |  |
 Grade II | 14 (50.0%) |  |  | 50 (59.5%) |  |  |
 Grade III | 8 (28.6%) |  |  | 20 (23.8%) |  |  |
 Grade IV | 2 (7.1%) |  |  | 4 (4.8%) |  |  |
AJCC clinical stage | Â | Â | Â | Â | Â | Â |
 Stage I | 17 (60.7%) |  |  | 68 (80.9%) |  |  |
 Stage II | 8 (28.6%) |  |  | 10 (11.9%) |  |  |
 Stage III | 1 (3.6%) |  |  | 4 (4.8%) |  |  |
 Stage IV | 2 (7.1%) |  |  | 2 (2.4%) |  |  |